In medical emergencies, intraosseous (IO) access is an effective way to administer fluids and drugs in the absence of intravenous access. IO has been the standard of care for pediatric patients since the 1980s. As of 2015, the American Heart Association (AHA) has recommended IO as an alternative in situations where prompt venous catheterization is not possible. IO is currently used as a short-term (24 hour duration), emergency vascular access solution for the emergent patient in both pre-hospital and hospital settings.
The NIO™, the next generation IO, provides vascular access in 10 seconds or less. The NIO™ is a single-use, automatic intraosseous device that provides rapid vascular access via the humeral head or tibia. The NIO™ does not require assembly or an external battery source. Furthermore, it is a single-use device that ensures sterility and convenience, making it cost-effective to store in ambulances, crash carts, and IFAK kits.
According to the article in the Bee Tribune on the global IO devices market, “The global intraosseous devices market is projected to reach a value of US$ 586.9 Mn by 2026, expanding at a CAGR of more than 5.5% from 2018 to 2026. The global market is expanding at a relatively higher growth rate due to increase in geriatric population, rising prevalence of various diseases and expansion in research, rising number of medical emergency situations, and developmental activities and approaches in healthcare sector in both developed and developing countries.”
full article here: https://beetribune.com/2019/08/13/global-intraosseous-devices-market-key-segments-and-regional-outlook/